Drug Trial Radar · NCT07412938
JKN2306 in Healthy Subjects: Single Ascending Dose and Food Effect Study
Last checked: Nov 20, 2026Latest source record: Feb 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
44
Actual
Start
Feb 12, 2025
Primary completion
Jul 2, 2025
Study completion Jul 2, 2025
Sponsor
- Lead sponsor
- Joincare Pharmaceutical Group Industry Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Feb 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This first-in-human, single-center study in China evaluated the safety, tolerability, and pharmacokinetics of single oral doses of JKN2306 tablets in healthy adult subjects and assessed the effect of a high-fat, high-calorie meal on the pharmacokinetics of JKN2306.
Conditions
- Acute Pain
Interventions
JKN2306Drug
JKN2306 tablet, oral
PlaceboDrug
matching placebo tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability of single oral doses of JKN2306Time frame: SAD: Baseline to Day 8 post-dose.FE: Baseline to Day 15 post-dose.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
China-Japan Friendship Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.